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Abstract
Background: Endogenously produced hydrogen sulfide (H2S) may have multiple functions in brain. An increasing
number of studies have demonstrated its anti-inflammatory effects. In the present study, we investigated the effect
of sodium hydrosulfide (NaHS, a H2S donor) on cognitive impairment and neuroinflammatory changes induced by
injections of Amyloid-β1-40 (Aβ1-40), and explored possible mechanisms of action.
Methods: We injected Aβ1-40 into the hippocampus of rats to mimic rat model of Alzheimer’s disease (AD). Morris
water maze was used to detect the cognitive function. Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) assay was performed to detect neuronal apoptosis. Immunohistochemistry analyzed the
response of glia. The expression of interleukin (IL)-1β and tumor necrosis factor (TNF)-α was measured by
enzyme-linked immunosorbent assay (ELISA) and quantitative real-time polymerase chain reaction (qRT-PCR). The
expression of Aβ1-40, phospho-p38 mitogen-activated protein kinase (MAPK), phospho-p65 Nuclear factor (NF)-κB,
and phospho-c-Jun N-terminal Kinase (JNK) was analyzed by western blot.
Results: We demonstrated that pretreatment with NaHS ameliorated learning and memory deficits in an Aβ1-40 rat
model of AD. NaHS treatment suppressed Aβ1-40-induced apoptosis in the CA1 subfield of the hippocampus.
Moreover, the over-expression in IL-1β and TNF-α as well as the extensive astrogliosis and microgliosis in the
hippocampus induced by Aβ1-40 were significantly reduced following administration of NaHS. Concomitantly,
treatment with NaHS alleviated the levels of p38 MAPK and p65 NF-κB phosphorylation but not JNK
phosphorylation that occurred in the Aβ1-40-injected hippocampus.
Conclusions: These results indicate that NaHS could significantly ameliorate Aβ1-40-induced spatial learning and
memory impairment, apoptosis, and neuroinflammation at least in part via the inhibition of p38 MAPK and p65
NF-κB activity, suggesting that administration of NaHS could provide a therapeutic approach for AD.
Keywords: Alzheimer’s disease, Amyloid-β, Neuroinflammation, Hydrogen sulfide, p38 mitogen-activated protein
kinase, p65 nuclear factor-κB
Background
Alzheimer’s disease (AD) is a devastating and progres-
sive neurodegenerative disorder characterized by extra-
cellular deposition of Amyloid-β (Aβ) protein and
intraneuronal neurofibrillary tangles (NFTs). Microglia
have been implicated in the progressive nature of nu-
merous neurodegenerative or neuroinflammatory dis-
eases such as AD [1]. The premise of deleterious
microglial activation in AD has been supported by ana-
lysis of postmortem brains of patients with AD [2],
where microglial over-activation occurred before neuro-
pil damage, suggesting that it plays a causal role in the
development of AD. The core of the senile plaque is
the deposition of Aβ and the activated microglia and
astroglia are around the senile plaque. In these glias, nu-
merous inflammation factors including interleukin-1β
(IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α) and inducible nitric oxide synthase (iNOS), and
cyclooxygenase-2 (COX-2), and so on, are overexpressed
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[3,4]. Accumulating evidence indicates that neuroinflam-
matory processes may contribute to the pathophysiology
of AD. However, traditional anti-inflammatory therapies
such as non-steroidal anti-inflammatory drugs (NSAIDs)
have produced mixed and conflicting results [5], high-
lighting the need for new and more specific anti-
inflammatory targets.
Hydrogen sulfide (H2S) is best known as a poisonous
gas with an extremely unpleasant odor. It is endogen-
ously produced in the brain from cysteine by cystathio-
nine β-synthase (CBS) and cystathione γ-lyase (CGL)
[6]. CBS is the main H2S producing enzyme in brain. A
recent study showed that 3-mercaptopyruvate sulfur-
transferase (3MST) in combination with cysteine amino-
transferase (CAT) also produces H2S from cysteine. In
addition, 3MST is localized to neurons, and the levels of
bound sulfane sulfur, the precursor of H2S, are greatly
increased in the cells expressing 3MST and CAT but not
increased in cells expressing functionally defective mu-
tant enzymes [7]. Numerous studies showed that H2S
has anti-oxidant, anti-apoptotic effects in neuron and
glial cells [8,9]. H2S induces alterations in Ca
2+ in
astrocytes and microglia [10,11], suggesting it may have
anti-inflammatory properties. H2S produces an anti-
inflammatory effect in lipopolysaccharide (LPS)-induced
inflammation in both primary cultured microglia and
immortalized murine BV-2 microglial cells [12]. The
levels of S-adenosylmethionine (SAM), an activator of
CBS, are lower in AD brains than that in the brains of
normal individuals [13]. Another study showed that H2S
is an endogenous anti-inflammatory and neuroprotective
agent, and H2S releasing drugs may have therapeutic po-
tential in neurodegenerative disorders of aging such as
AD and Parkinson’s disease (PD) [14].
The above-mentioned roles of H2S raise the possibility
that H2S may be associated with the pathology of AD.
However, so far, a possible role for H2S as an anti-
inflammatory agent in rat model of AD has not been ex-
tensively evaluated. The focus of the present study was
to elucidate the effect of NaHS on cognitive impairment
and neuroinflammatory changes in rat model of AD as
well as possible mechanisms of action.
Methods
Surgery and drug administration
Healthy male Wistar rats (220 to 250 g) were randomly
divided into four groups (n= 56 for each group): sham
(control) group, sham+NaHS group, Aβ1-40 group, and
Aβ1-40 +NaHS group. Rats in the Aβ1-40 +NaHS group
were administered with NaHS (Sigma, USA) by intraper-
itoneal injection (i.p.) at a dose of 5 mg/kg once daily, 3
days before surgery and thereafter continuously for 9
days[15,16]. Three days after treatment with NaHS,
anesthesia was induced by chloral hydrate (35 mg/100 g
weight, i.p.). Aβ1-40 (10 nmol in 10 μL of sterile PBS)
was incubated at 37°C for 1 week to induce the aggrega-
tion of Aβ1-40 [17]. The aggregated Aβ1-40 and vehicle
was injected slowly over 10 min into the right dentate
gyrus (DG) of rats at the following coordinates: anterior/
posterior −3.3 mm, media/lateral 2.0 mm, and dorsal/
ventral −3.3 mm ventral to the skull surface. The rectal
temperature was maintained at 36°C to 37°C for all ani-
mals throughout the experiment. All animal experiments
were performed according to protocols approved by the
local animal care committee.
Morris water maze
The Morris water maze task was evaluated as previously
described [18] with slight modification. Trials were per-
formed during days 8 to 11 after the injection of Aβ1-40.
The task for all of the animals in each trial consisted of
finding a hidden clear plastic platform (10 cm diameter)
that was placed 50 cm away from the wall of the water
maze (150 cm in diameter, 60 cm in depth) and 1 cm
below the water. The platform remained in the same
position for all trials and sessions. The starting quadrant
was randomized every day, with all animals using the
same order. The animals were faced towards the pool
wall before being released. The time required to reach
the hidden platform and the swimming speed were
recorded. The animals were allowed to rest 30 s on the
platform between trials. If an animal failed to reach the
platform in 120 s, it was manually guided to the plat-
form. Each animal underwent two sessions (each con-
tains four trials: NE; NW; SE; SW) per day for 4
consecutive days. Before surgery, animals were screened
(without platform in the pool) for any rats that could
not swim. Seven days after the injection of Aβ1-40, ani-
mals were examined as above.
Immunohistochemistry and TUNEL staining
Immunohistochemistry was performed on the eighth day
after Aβ1-40 injection. After being microwaved for 5 min
and washed three times in PBS (pH 7.4), sections were
successively incubated with 0.3% H2O2 in methanol for
10 min, 10% normal goat serum in PBS for 20 min, and
primary antibody (anti-GFAP, anti-OX42, Millipore,
USA) dissolved in 2% normal goat serum, 0.3% Triton
X-100, 0.05% NaN3 in PBS at 4°C overnight, and then
37°C for 30 min. After rinsing three times in PBS, the
sections were incubated with biotinylated anti-mouse or
anti-rabbit secondary antibodies (Boster, China) in PBS
for 30 min at 37°C, then incubated with avidin-biotin-
peroxidase solution (SABC kit, Boster, China) and color-
ized with a DAB kit (Boster, China).
To detect cells undergoing apoptosis, TUNEL tech-
nique was performed according to the manufacturer’s
protocol supplied within the in situ Cell Death Detection
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Kit. The sections were immersed in 3% H2O2 for inacti-
vation of endogenous hydrogen peroxidase activity.
After rinsing with PBS, the sections were incubated
with proteinase K solution at 37°C for 20 min to en-
hance the permeability. Then they were incubated for
60 min at 37°C with TUNEL reaction mixture and
again incubated for 30 min at 37°C with converter-
POD. The sections were rinsed in PBS, incubated for
10 min with DAB substrate solution and rinsed again
with PBS. Counter staining was done with 0.5% methyl
green. Positive and negative controls were carried out
on slides from the same block. For TUNEL staining, 10
fields were chosen from each group and the percent of
TUNEL-positive cells were calculated according to this
relation: % TUNEL-positive neurons = (TUNEL-positive
neurons (brown)/TUNEL-positive neurons (brown) +
normal neurons (green)) × 100.
Measurement of pro-inflammatory cytokines
Hippocampal samples were homogenized in 10 wet
weight volumes of TBS, pH 8.0, containing a cocktail of
protease inhibitors (20 mg/mL each of pepstatin A,
aprotinin, phosphoramidon, and leupeptin, 0.5 mM
PMSF, and 1 mM EGTA). Samples were sonicated briefly
(10 W, 2 × 5 s) and centrifuged at 100,000 × g for 20 min
at 4°C. The soluble fraction (supernatant) was used for
IL-1β and TNF-α ELISAs (R&D Systems, USA).
Real time RT-PCR analysis
Expressions of genes were further confirmed by real
time PCR. Total RNA from hippocampus tissues were
extracted using TriZol reagent (Invitrogen). Reverse
transcription was performed with an ExScript RT Re-
agent Kit (Takara Bio Inc., China). Real-time PCR ana-
lysis was undertaken using SYBR Premix Ex Taq (Takara
Bio Inc., China). The primers sequences for IL-1β were
50-GCT GTG GCA GCT ACC TAT GTC TTG-30
(sense) and 50-AGG TCG TCA TCA TCC CAC GAG-30
(antisense). The primer sequences for TNF-α were 50-
GTG ATC GGT CCC AAC AAG GA-30 (sense) and 50-
CTC CCA CCC TAC TTT GCT TGT G-30 (antisense).
The primer sequences for β-actin were 50-TGA CAG G
TG CAG AAG GAG A-30 (sense) and 50-TAG AGC
CAC CAA TCC ACA CA-30 (antisense). The real-time
PCR conditions were as follows: initial denaturation at
95°C for 10 s followed by 39 cycles of 95°C for 5 s and
60°C for 20 s. The expression levels of the genes were
quantified by comparison with a standard curve and
normalized relative to levels of ß-actin.
Western blot analysis
Expression of Aβ1-40, phospho-p38 MAPK, phospho-p65
NF-κB, and phospho-JNK was analyzed by western blot.
Thirty μg protein of each sample was heated at 100°C
for 5 min with a loading buffer containing 0.125 M
Tris–HCl (pH 6.8), 20% glycerol, 4% SDS, 10% mercap-
toethanol, and 0.002% bromophenol blue. It was then
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) using 10% acrylamide gels.
The proteins were transferred onto PVDF membranes
(pore size, 0.45 μm). Blotting membranes were incubated
with 3% bovine serum albumin (BSA) in tris buffered sa-
line with tween (TBST) (10 mmol/L Tris (pH 7.5),
150 mmol/L NaCl, 0.05% Tween-20) and probed with
corresponding primary antibodies (anti-Aβ1-40, anti-
phospho-p65 NF-κB, anti-phospho-p38 MAPK, and
anti-phospho-JNK, CST, USA) at 4°C overnight. After
incubation with horseradish peroxidase-coupled second-
ary antibodies for 2 h at room temperature, bands were
quantitated by densitometry (UVP Upland, CA).
Statistical analysis
All values were expressed as the mean± standard error
of the mean (SEM). For the behavioral experiments, the
escape latency during the training tests was determined
by two-way repeated factor analysis of variance
(ANOVA) with Student-Newman-Keuls tests. All other
assessments were analyzed using a one-way ANOVA fol-
lowed by Student-Newman-Keul’s or Dunnett’s post-hoc
analysis. In all cases, P < 0.05 was considered significant.
Results
NaHS prevented Aβ-induced impairment of spatial
learning
To investigate whether the pre-treatment with NaHS led
to functional improvement, we employed the Morris
water maze task to examine hippocampus-involved
learning and memory. All animals were able to swim
normally and find the hidden platform during the train-
ing trials. After being trained twice per day for two con-
secutive sessions, sham and sham+NaHS rats were able
to reach the hidden platform in a shorter time during
the training (Figure 1A). However, the learning and
memory abilities of Aβ1-40-injected rats were signifi-
cantly impaired compared with the sham group
(P < 0.01) (Figure 1A). A significant decrease in escape
latency was observed in the NaHS+Aβ1-40 group com-
pared with the Aβ1-40-injected group (P < 0.01)
(Figure 1A). There was no significant difference in aver-
age swim speed among the groups (Figure 1B). These
results clearly indicate that NaHS treatment significantly
ameliorated severe deficiencies in spatial cognitive per-
formance induced by Aβ1-40.
In the probe trial of the Morris water maze test, Aβ1-40
had a significant effect on the time and distance in target
quadrant compared with the sham group (P < 0.01).
Compared with the Aβ1-40-injected group, NaHS +Aβ1-40
Xuan et al. Journal of Neuroinflammation 2012, 9:202 Page 3 of 11
http://www.jneuroinflammation.com/content/9/1/202
rats displayed more time and distance swimming in the
target quadrant (P < 0.05) (Figure 1C, D).
NaHS suppressed Aβ1-40-induced apoptosis in
Aβ1-40-injection rat model
To confirm the protective effect of NaHS on Aβ1-40-
induced apoptosis, sections through the hippocampus
were also examined for the presence of fragmented
DNA via TUNEL assay. Microscopic inspection of the
hippocampal sections from sham and sham+NaHS rats
revealed morphologically normal neurons with no
TUNEL reaction. After the injection of Aβ1-40, a signifi-
cant number of TUNEL-positive pyramidal neurons with
different degrees of DNA fragmentation were detected
in the CA1 subfield of the hippocampus (P < 0.01 vs.
sham). Treatment with NaHS significantly reduced the
number of TUNEL-positive neurons (P < 0.01 vs. Aβ1-40)
(Figure 2A-E).
NaHS lowered protein levels of Aβ1-40 in the
hippocampus of rats
Progressive accumulation of Aβ peptides are a major
factor in the development of AD pathogenesis [19].
Immunoblot analysis was used to assess the effect of
NaHS on levels of Aβ1-40 in area CA1. Infusion of Aβ
peptides in normal rats resulted in a marked (P < 0.01)
accumulation of Aβ1-40 levels. NaHS treatment signifi-
cantly decreased levels of Aβ1-40, in NaHS +Aβ1-40 rats
by approximately 31%, compared to those in Aβ rats
(Aβ: 1.75 ± 0.19; NaHS +Aβ1-40:1.21 ± 0.07, n= 5 rats/
group) (Figure 3A, B).
NaHS decreased Aβ-induced astrocytic and microglial
response
Intrahippocampal injection of Aβ oligomers has been
shown to have extended neuroinflammatory responses
displaying a significant increase in astrocytic and micro-
glial response that is associated with age and amyloid
deposition [20,21]. To evaluate the effect of NaHS on
the glial response, we performed GFAP (astrocytic) and
OX42 (microglial) staining in the hippocampus. GFAP
immunostaining demonstrated that injection of Aβ1-40
caused reactive gliosis as demonstrated by upregulation
of GFAP expression and the presence of hypertrophic
astrocytes in the hippocampus (P < 0.01) (Figures 4A-E
and 4a-d). In the NaHS+Aβ1-40 group the number of
Figure 1 Effect of NaHS on Aβ1-40-induced cognitive impairment. Aβ1-40 was slowly injected into the hippocampus, and subjected to the
Morris water maze test 7 days later. (A) The escape latency in the navigation test. (B) The average swim speed among the groups. (C) The
percent of (%) time in the targeted quadrant where the platform had been located in the spatial exploring test. (D) The percent of (%) distance
in the targeted quadrant where the platform had been located in the spatial exploring test. Data presented as mean± S.E.M., n=10-13. **P< 0.01
vs. sham; #P< 0.05 vs. Aβ1-40.
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GFAP-immunoreactive astrocytes was significantly
reduced compared to the Aβ1-40-injected group
(P < 0.05) (Figures 4A-E and 4a-d). A similar effect was
exerted in the NaHS+Aβ1-40 group where the intensity
of OX42-positive microglia was significantly reduced
compared to the Aβ1-40-injected group (Figure 4F-J).
NaHS attenuated Aβ-induced increases in the levels of
cytokine production and mRNA in the hippocampus
We next addressed whether NaHS was able to amelior-
ate a generalized pro-inflammatory response from glia.
The pro-inflammatory cytokines response was tested by
measuring levels of IL-1β and TNF-α in hippocampal
brain homogenates. Aβ1-40 injection significantly
increased the levels of IL-1β and TNF-α, and NaHS was
able to significantly reduce this response, although levels
did not return to that of control (Figure 5A, B).
The effects of NaHS on the mRNA of IL-1β and TNF-
α were investigated by real-time RT-PCR. Compared
with the sham group, injection of Aβ1-40 in the hippo-
campus highly increased the mRNA of IL-1β and TNF-
α, which were approximately 4.7-fold and 2.4-fold, re-
spectively (P < 0.01, Figure 5C, D). However, compared
to the Aβ1-40 group, treatment with NaHS significantly
decreased the mRNA expressions of these selected genes
(P < 0.01, Figure 5C, D).
NaHS decreased the activation of phospho-p38 MAPK
and phospho-p65 NFκB, but not phospho-JNK in the
hippocampus
To further explore the molecular mechanisms under-
lying the inhibitory effect of NaHS on the expressions of
IL-1β and TNF-α, the expressions of phospho-p38
MAPK, phospho-p65 NFκB, and phospho-JNK were
determined by western blot analysis. Aβ1-40 injection
into the hippocampus significantly enhanced the p38
MAPK, p65 NF-κB, and JNK phosphorylation (P < 0.01,
Figure 6A, B). However, treatment with NaHS caused a
Figure 2 Effects of NaHS on DNA fragmentation in the hippocampus of rats injected with Aβ1-40. (A, B) No TUNEL-reactive cell was
detected in the hippocampus from sham and sham+NaHS rats. (C) The significant number of degenerating pyramidal neurons, labeled with the
TUNEL technique was observed in the CA1 subfield of the hippocampus. (D) The number of TUNEL-positive neurons significantly decreased in
the hippocampus from Aβ1-40-injected rats receiving NaHS. Scale bar: 40 μm. Arrows point to degenerating pyramidal neurons with their nuclei
stained with TUNEL technique. (E) Quantitative analysis of % TUNEL-positive neurons. Data are given as mean± S.E.M.. **P< 0.01 vs. sham;
##P< 0.01 vs. Aβ1-40.
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Figure 3 NaHS pre-treatment reduces Aβ1-40 levels. Aβ1-40 rats were treated with NaHS (5 mg/kg i.p. once daily). (A) Western blot of Aβ1-40
protein contents. In hippocampal area CA1 the basal levels of Aβ1-40 peptides decreased significantly after NaHS treatment. (B) The relative optical
density was normalized to β-Actin. Results are expressed as mean±S.E.M. with five rats in each group. **P<0.01 vs. sham; #P<0.05 vs. Aβ1-40.
Figure 4 Effect of NaHS on Aβ1–40-induced the activation of glia in the DG region of rat hippocampus. (A-E, a-d) The distribution and
number of GFAP-immunoreactive astrocytes in sham, sham+NaHS, Aβ1-40, and NaHS+Aβ1-40 rats. Scale bar, 500 μm (A-D) and 50 μm (a-d). (F-J)
Representative photographs and number of OX-42-immunopositive cells in sham, sham+NaHS, Aβ1-40, and NaHS+Aβ1-40 rats. Scale bar: 250 μm. Six
tissue sections per rat were used for the analysis (n=8-10). Data are presented as the mean± S.E.M. **P<0.01 vs. sham; ##P<0.01, #P<0.05 vs. Aβ1-40.
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significant decrease in the phosphorylation of p38
MAPK and p65 NF-κB but not JNK (P < 0.05,
Figures 6C, D). Our results show that NaHS treatment
suppressed Aβ1-40-induced activation of p38 MAPK and
p65 NF-κB but not JNK, which may contribute to the in-
hibition of NaHS on the Aβ1-40-induced IL-1β and TNF-
α production.
Discussion
The deposition of Aβ in brain areas involved in cognitive
functions is assumed to initiate a pathological cascade
that results in synaptic dysfunction, synaptic loss, and
neuronal death [22]. It has been proposed that Aβ1-40
aggregates play an important role in the pathogenesis of
AD [23]. Numerous reports have showed that the injec-
tion of Aβ1-40 into rat hippocampus provides an effective
model to mimic some of the pathologic and behavioral
changes of AD [24-26]. In our study, we demonstrated
that Aβ1-40 injection could induce memory deficits and
NaHS treatment could also effectively ameliorate Aβ-
induced impairment of spatial learning.
Memory impairment in Aβ-injected rats was associated
with a significant reduction in apoptosis. Apoptosis has
been consistently implicated in Aβ-induced neuronal dam-
age in vitro, in animal models of AD, and also postmortem
studies of AD brain [27-29]. The mechanisms underlying
Aβ-mediated neurotoxicity still remain to be elucidated,
but mounting evidence suggests the involvement of Aβ-
induced neuroinflammatory in the disease process with
AD. Studies have shown that Aβ induces the production
of neuroinflammatory molecules, which may contribute to
the pathogenesis of numerous neurodegenerative diseases
[30-32]. However, lots of studies have also demonstrated
that anti-inflammatory compounds could exhibit neuro-
protective effects in damaged brain cells [33-35]. Central
administration of NaHS prevented Aβ1-40-evoked apop-
tosis. Decrease in TUNEL-positive neurons may stem
from its general suppression of the neuroinflammatory
context in the Aβ1-40-inflicted hippocampus, thus attenu-
ating the inflammatory cell death.
Evidence suggests that inflammatory reaction induced
by Aβ in the AD involves astrogliosis, microgliosis,
Figure 5 Effect of NaHS on the IL-1β, TNF-α production, and mRNA expressions. IL-1β and TNF-α levels in the hippocampus were
measured via ELISA. The expressions of IL-1β and TNF-α mRNA in the hippocampus were detected by real time RT-PCR. Aβ1-40 injection into the
hippocampus significantly increased the IL-1β, TNF-α production, and mRNA expressions. Treatments with NaHS significantly decreased the levels
and mRNA over-expressions of IL-1β and TNF-α. (A) The level of IL-1β. (B) The level of TNF-α. (C) The expressions of IL-1β mRNA. (D) The
expressions of TNF-α mRNA. Data are mean± S.E.M., n= 4. **P< 0.01 vs. sham; ##P< 0.01, #P<0.05 vs. Aβ1-40.
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cytokine elevation, and changes in acute phase proteins
[22,36]. Activated astrocytes and microglia can secrete
inflammatory cytokines and mediators that promote the
formation of Aβ and NFTs through numerous signal
transduction pathways [37]. In the brains of AD rats, the
production of IL-1β and TNF-α play an important role
in augmenting inflammatory reaction and formation of
Aβ [38]. Several reports have provided evidence demon-
strating a role for IL-1β in the etiology of AD based
largely on the finding that IL-1β expression in different
brain areas in AD and also in the cerebrospinal fluid of
AD patients [39,40]. Consistently, the injection of Aβ
increases the hippocampal mRNA expression of both
TNF-α and inducible nitric oxide synthase (iNOS), of
which the former was stronger, and the knock-out of
TNF-α (TNF-α (−/−)) in mouse prevented the increase
of iNOS mRNA in the hippocampus and the impairment
of recognition memory in mice induced by Aβ [41]. It
has been proposed that elevated levels of pro-
inflammatory cytokines, including TNF-α, may inhibit
Figure 6 Western blotting analysis of the relative protein contents. (A, C) Western blot of various protein contents for phospho-p38 MAPK,
phospho-p65 NFκB, and phospho-JNK. (B, D) The relative optical density was normalized to β-Actin. Data are mean± S.E.M., n= 4. **P< 0.01
*P< 0.05 vs. sham(control); #P< 0.05 vs. Aβ1-40.
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phagocytosis of Aβ in AD brains thereby hindering effi-
cient plaque removal by resident microglia [42]. In our
studies, we demonstrated that the hippocampus of the
Aβ1-40 group had the activation of astrogliosis and
microgliosis as well as the strong increase of IL-1β and
TNF-α compared with the sham group, indicating that
the two inflammatory cytokines were involved in the in-
flammatory response in AD rats.
Our results demonstrated that NaHS treatment
decreased Aβ1-40-induced astrocytic and microglial re-
sponse as well as inflammatory cytokines expression. A
previous study showed that H2S was synthesized in brain
primarily by the enzyme CBS, and that astrocytes were
the most active producers of H2S, with much smaller
quantities being generated by microglia [43]. H2S pro-
duction is suppressed by inflammatory stimulation of
microglia and astrocytes, and this suppression reduces
the natural anti-inflammatory effect of H2S [14]. H2S
has been reported to exhibit marked anti-inflammatory
activity in LPS-induced lung, liver, and kidney tissue in-
flammatory damage in the mouse [44]. Another result
reveals that H2S releasing NSAIDS S-aspirin and S-
diclofenac attenuates the neuroinflammation induced by
activation of glia [45]. Administration of NaHS signifi-
cantly attenuates LPS-induced cognitive impairment
through reducing the overproduction of proinflamma-
tory mediators, and accompanied by an increase of H2S
levels [46]. However, there is no direct evidence that
H2S attenuates inflammatory initiated neuronal death,
which is closely associated with the pathogenesis of sev-
eral neurodegenerative diseases including AD.
To further understand the molecular mechanisms of
the effects of NaHS on the expressions of IL-1β and
TNF-α, the expressions of phospho-p38 MAPK,
phospho-p65 NF-κB, and phospho-JNK were analyzed
by western blot. Numerous studies demonstrate that in-
jection of Aβ into the hippocampus, cortex, and nucleus
basalis induces the activity of p38 MAPK, NF-κB, and
JNK in rat [47-50]. p38 MAPK activation has been
implicated in the pathogenesis of AD, and significant in-
crease of MAPK kinase 6 (MKK6), one of the upstream
activators of p38 MAPK, is observed in hippocampal
and cortical regions of individuals with AD compared
with age-matched controls [51]. Chronic exposure of
human microglia to Aβ1-42 led to enhanced p38 MAPK
expression [36]. NF-κB is known to upregulate the
expressions of cytokines, chemokines, adhesion mole-
cules, acute phase proteins, and inducible effector
enzymes. NF-κB is composed of several protein subunits,
among which p65 has been extensively studied. In AD
brains, p65 NF-κB immunoreactivity is greater in neu-
rons and astrocytes surrounding amyloid plaques
[52,53]. Additionally, it has been reported that Aβ stimu-
lation leads to p65 NF-κB activation in cultured neurons
and glia [54]. One study has revealed that increased hip-
pocampal IL-1βconcentration, paralleled by increased
JNK activation in AD brain [51]. The activation of JNK
has been described in cultured neurons after Aβ expos-
ure, and their inhibition attenuates Aβ toxicity [49,55].
Corroborating these findings, the present results show
that increased hippocampal concentration of inflamma-
tory cytokines stimulated by Aβ is accompanied by
phosphorylation of p38 MAPK, p65 NF-κB, and JNK.
Our data also suggest that the effects of H2S against
the released levels of pro-inflammatory cytokines such
as IL-1β and TNF-α may include the capability of this
gas to reduce the levels of phospho-p38 MAPK and
phospho-p65 NF-κB but not phospho-JNK. This is con-
sistent with reports that S-diclofenac decreases the acti-
vation of NFκB and other pro-inflammatory cytokines in
rat plasma and liver homogenates [44] and that NaHS
attenuates LPS-induced inflammation by inhibition of
p38 MAPK and p65 NF-κB in rodent microglia and rat
[12,46].
Conclusions
In conclusion, our results clearly demonstrated that: (1)
a single injection of Aβ1-40 into the hippocampus pro-
duced cognitive impairment in rats, apoptosis, and the
glial response, with concomitant production of IL-1β
and TNF-α, and these effects occurred via activation of
p38 MAPK, p65 NF-κB, and phospho-JNK in rat’s
hippocampus; and (2) pretreatment with NaHS signifi-
cantly attenuated Aβ1-40-induced cognitive deficits,
apoptosis, and the glial response, with concomitant inhi-
bitions of IL-1β and TNF-α production, as well as
repressed Aβ1-40-induced activation of p38 MAPK and
p65 NF-κB.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AX designed the study, conducted molecular assays and the data analysis.
DL participated in the design of the study. JIANL performed the TUNEL
assay. WJ carried out the RT-PCR. MZ performed the immunohistochemistry.
LH performed the Morris water maze. JIL participated in the ELISA and
performed the statistical analysis. AX, DL, WJ, MZ, LH, and JIANL drafted and/
or criticized the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This research was co-financed by grants from Natural Science Foundation of
China (No. 30900728), Medical Scientific Research Foundation of Guangdong
Province (No. A2010228), Science Foundation of Education Bureau of
Guangzhou City (No. 10A156).
Author details
1Department of Anatomy, Guangzhou Medical University, Guangzhou, China.
2Department of Physiology, Guangzhou Medical University, Guangzhou,
China. 3Department of Urology, Minimally Invasive Surgery Center,
Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital
of Guangzhou Medical University, Guangzhou, China. 4Department of
Neurobiology, Southern Medical University, Guangzhou, China.
Xuan et al. Journal of Neuroinflammation 2012, 9:202 Page 9 of 11
http://www.jneuroinflammation.com/content/9/1/202
Received: 8 May 2012 Accepted: 4 August 2012
Published: 17 August 2012
References
1. Mildner A, Schlevogt B, Kierdorf K, Böttcher C, Erny D, Kummer MP, Quinn
M, Brück W, Bechmann I, Heneka MT, Priller J, Prinz M: Distinct and non-
redundant roles of microglia and myeloid subsets in mouse models of
Alzheimer’s disease. J Neurosci 2011, 31:11159–11171.
2. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van
Gool WA: Neuroinflammation-an early event in both the history and
pathogenesis of Alzheimer’s disease. Neurodegener Dis 2010, 7:38–41.
3. Seabrook TJ, Jiang L, Maier M, Lemere CA: Minocycline affects microglia
activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006,
53:776–782.
4. Weldon DT, Rogers SD, Ghilard JR, Finke MP, Cleary JP, O’Hare E, Esler WP,
Maggio JE, Mantyh PW: Fibrillar beta-amyloid induces microglial
phagocytosis, expression of inducible nitric oxide synthase, and loss of a
select population of neurons in the rat CNS in vivo. J Neurosci 1998,
18:2161–2173.
5. Potter PE: Investigational medications for treatment of patients with
Alzheimer disease. J Am Osteopath Assoc 2010, Suppl 8:27–36.
6. Kamoun P: Endogenous production of hydrogen sulfide in mammals.
Amino Acids 2004, 26:243–254.
7. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, Kimura H:
3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and
bound sulfane sulfur in the brain. Antioxid Redox Signal 2009, 11:703–714.
8. Kimura Y, Kimura H: Hydrogen sulfide protects neurons from oxidative
stress. FASEB J 2004, 18:1165–1167.
9. Yin WL, He JQ, Hu B, Jiang ZS, Tang XQ: Hydrogen sulfide inhibits MPP
(+)-induced apoptosis in PC12 cells. Life Sci 2009, 85:269–275.
10. Lee SW, Hu YS, Hu LF, Lu Q, Dawe GS, Moore PK, Wong PT, Bian JS:
Hydrogen sulphide regulates calcium homeostasis in microglial cells. Glia
2006, 54:116–124.
11. Nagai Y, Tsugane M, Oka J, Kimura H: Hydrogen sulfide induces calcium
waves in astrocytes. FASEB J 2004, 18:557–559.
12. Hu LF, Wong PT, Moore PK, Bian JS: Hydrogen sulfide attenuates
lipopolysaccharide induced inflammation by inhibition of p38 mitogen-
activated protein kinase in microglia. J Neurochem 2007, 100:1121–1128.
13. Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are
severely decreased in Alzheimer’s disease. J Neurochem 1996,
67:1328–1331.
14. Lee M, Schwab C, Yu S, McGeer E, McGeer PL: Astrocytes produce the
antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol
Aging 2009, 30:1523–1534.
15. Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ: Hydrogen sulfide
attenuates lipopolysaccharide-induced cognitive impairment: A pro-
inflammatory pathway in rats. Pharmacol Biochem BE 2010, 96:52–58.
16. Qu K, Chen CP, Halliwell B, Moore PK, Wong PT: Hydrogen sulfide is a
mediator of cerebral ischemic damage. Stroke 2006, 37:889–893.
17. Huang HJ, Liang KC, Chen CP, Chen CM, Hsieh-Li HM: Intrahippocampal
administration of A beta(1–40) impairs spatial learning and memory in
hyperglycemic mice. Neurobiol Learn Mem 2007, 87:483–494.
18. Morris R: Developments of a water-maze procedure for studying spatial
learning in the rat. J Neurosci Methods 1984, 11:47–60.
19. Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA: Chronic nicotine
restores normal Aβ levels and prevents short-term memory and E-LTP
impairment in Aβ rat model of Alzheimer’s disease. Neurobiol Aging 2011,
32:834–844.
20. Bagheri M, Roghani M, Joghataei MT, Mohseni S: Genistein inhibits
aggregation of exogenous amyloid-beta1-40 and alleviates astrogliosis in
the hippocampus of rats. Brain Res 2012, 1429:145–154.
21. Miguel-Hidalgo JJ, Cacabelos R: Beta-amyloid(1–40)-induced
neurodegeneration in the rat hippocampal neurons of the CA1 subfield.
Acta Neuropathol 1998, 95:455–465.
22. Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure
in Alzheimer’s disease. Neuron 2004, 44:181–193.
23. Hashimoto T, Adams KW, Fan Z, McLean PJ, Hyman BT: Characterization of
oligomer formation of amyloid-beta peptide using a split-luciferase
complementation assay. J Biol Chem 2011, 286:27081–27091.
24. Shin RW, Ogino K, Kondo A, Saido TC, Trojanowski JQ, Kitamoto T, Tateishi J:
Amyloid beta-protein (Abeta) 1–40 but not Abeta1-42 contributes to the
experimental formation of Alzheimer disease amyloid fibrils in rat brain.
J Neurosci 1997, 17:8187–8193.
25. Yamaguchi Y, Miyashita H, Tsunekawa H, Mouri A, Kim HC, Saito K, Matsuno
T, Kawashima S, Nabeshima T: Effects of a novel cognitive enhancer, spiro
[imidazo-[1,2-a] pyridine −3,2- indan]-2(3H)-one (ZSET1446), on learning
impairments induced by amyloid-beta1-40 in the rat. J Pharmacol Exp
Ther 2006, 317:1079–1087.
26. Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N,
Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M: Amyloid beta-
protein (Abeta)1-40 protects neurons from damage induced by Abeta1-
42 in culture and in rat brain. J Neurochem 2003, 87:609–619.
27. Yu Y, Zhou L, Sun M, Zhou T, Zhong K, Wang H, Liu Y, Liu X, Xiao R, Ge J,
Tu P, Fan DS, Lan Y, Hui C, Chui D: Xylocoside G reduces amyloid-β
induced neurotoxicity by inhibiting NF-κB signaling pathway in neuronal
cells. J Alzheimers Dis 2012, 30:263–275.
28. Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR,
Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK:
Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant
PS2 transgenic mouse model of Alzheimer’s disease. FASEB J 2002,
6:805–813.
29. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, Mee E:
In situ evidence for DNA fragmentation in Huntington’s disease striatum
and Alzheimer’s disease temporal lobes. Neuroreport 1995, 6:1053–1057.
30. Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway
HW, Luo W, Li Y, Caracciolo L, Russo I, Barlati S, Ray B, Lahiri DK, Bosetti F,
Greig NH, Rosi S: Tumor necrosis factor-α synthesis inhibitor 3,60-
dithiothalidomide attenuates markers of inflammation. Alzheimer
pathology and behavioral deficits in animal models of
neuroinflammation and Alzheimer’s disease. J Neuroinflammation 2012,
9:106.
31. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rübe CE, Walter J, Heneka
MT, Hartmann T, Menger MD, Fassbender K: TLR2 is a primary receptor for
Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J
Immunol 2012, 188:1098–1107.
32. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M,
Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T:
Longitudinal, quantitative assessment of amyloid, neuroinflammation,
and anti-amyloid treatment in a living mouse model of Alzheimer’s
disease enabled by positron emission tomography. J Neurosci 2007,
27:10957–10968.
33. Zhu LH, Bi W, Qi RB, Wang HD, Wang ZG, Zeng Q, Zhao YR, Lu DX: Luteolin
reduces primary hippocampal neurons death induced by
neuroinflammation. Neurol Res 2011, 33:927–934.
34. Lee JY, Cho E, Ko YE, Kim I, Lee KJ, Kwon SU, Kang DW, Kim JS: Ibudilast, a
phosphodiesterase inhibitor with anti-inflammatory activity, protects
against ischemic brain injury in rats. Brain Res 2012, 1431:97–106.
35. Liu T, Jin H, Sun QR, Xu JH, Hu HT: The neuroprotective effects of
tanshinone IIA on β-amyloid-induced toxicity in rat cortical neurons.
Neuropharmacology 2010, 59:595–604.
36. Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG: Broad-
spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-
induced cell signaling and functional responses in human microglia. J
Neurosci 2006, 26:11652–11664.
37. Peila R, Launer LJ: Inflammation and dementia: epidemiologic evidence.
Acta Neurol Scand Suppl 2006, 185:102–106.
38. Morales I, Farías G, Maccioni RB: Neuroimmunomodulation in the
pathogenesis of Alzheimer’s disease. Neuroimmunomodulation 2010,
17:202–204.
39. Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V,
Baloyiannis SI: Cytokines in Alzheimer’s disease and vascular dementia. Int
J Neurosci 2008, 118:1659–1672.
40. Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB, Gattaz WF, Teixeira
AL: Increased serum IL-1beta level in Alzheimer’s disease and mild
cognitive impairment. Dement Geriatr Cogn Disord 2009, 28:507–512.
41. Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K,
Nabeshima T: Restraining tumor necrosis factor-alpha by thalidomide
prevents the amyloid beta-induced impairment of recognition memory
in mice. Behav Brain Res 2008, 189:100–106.
42. Koenigsknecht-Talboo J, Landreth GE: Microglial phagocytosis induced by
fibrillar beta-amyloid and IgGs are differentially regulated by
proinflammatory cytokines. J Neurosci 2005, 25:8240–8249.
Xuan et al. Journal of Neuroinflammation 2012, 9:202 Page 10 of 11
http://www.jneuroinflammation.com/content/9/1/202
43. Abe K, Kimura H: The possible role of hydrogen sulfide as an
endogenous neuromodulator. J Neurosci 1996, 16:1066–1071.
44. Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FB, Whiteman
M, Salto-Tellez M, Moore PK: Hydrogen sulfide is a novel mediator of
lipopolysaccharide-induced inflammation in the mouse. FASEB J 2005,
19:1196–1198.
45. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL: Hydrogen sulfide-
releasing NSAIDs attenuate neuroinflammation induced by microglial
and astrocytic activation. Glia 2010, 58:103–113.
46. Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ: Hydrogen sulfide
attenuates lipopolysaccharide-induced cognitive impairment: a pro-
inflammatory pathway in rats. Pharmacol Biochem Behav 2010, 96:52–58.
47. Giovannini MG, Scal C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu
G, Casamenti F: Beta-amyloid-induced inflammation and cholinergic
hypofunction in the rat brain in vivo: involvement of the p38MAPK
pathway. Neurobiol Dis 2002, 11:257–274.
48. Ji C, Aisa HA, Yang N, Li Q, Wang T, Zhang L, Qu K, Zhu HB, Zuo PP:
Gossypium herbaceam extracts inhibited NF-kappaB activation to
attenuate spatial memory impairment and hippocampal
neurodegeneration induced by amyloid-beta in rats. J Alzheimers Dis
2008, 14:271–283.
49. Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA: Modulation of
amyloid-beta-induced and age-associated changes in rat hippocampus
by eicosapentaenoic acid. J Neurochem 2007, 103:914–926.
50. Wang C, Li J, Liu Q, Yang R, Zhang JH, Cao YP, Sun XJ: Hydrogen-rich
saline reduces oxidative stress and inflammation by inhibit of JNK and
NF-κB activation in a rat model of amyloid-beta-induced Alzheimer’s
disease. Neurosci Lett 2011, 491:127–132.
51. Zhu X, Rottkamp CA, Hartzler A, Sun Z, Takeda A, Boux H, Shimohama S,
Perry G, Smith MA: Activation of MKK6, an upstream activator of p38, in
Alzheimer’s disease. J Neurochem 2001, 79:311–318.
52. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C: Transcription
factor NF-kappaB is activated in primary neurons by amyloid beta
peptides and in neurons surrounding early plaques from patients with
Alzheimer disease. Proc Natl Acad Sci U S A 1997, 94:2642–2647.
53. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T:
Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer’s
disease brains. Neurosci Lett 1997, 237:17–20.
54. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L:
SIRT1 protects against microglia-dependent amyloid-beta toxicity
through inhibiting NF-kappaB signaling. J Biol Chem 2005,
280:40364–40374.
55. Ebenezer PJ, Weidner AM, LeVine H 3rd, Markesbery WR, Murphy MP, Zhang
L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Gavilán E, Keller JN: Neuron
specific toxicity of oligomeric amyloid-β: role for JUN-kinase and
oxidative stress. J Alzheimers Dis 2010, 22:839–848.
doi:10.1186/1742-2094-9-202
Cite this article as: Xuan et al.: Hydrogen sulfide attenuates spatial
memory impairment and hippocampal neuroinflammation in beta-
amyloid rat model of Alzheimer’s disease. Journal of Neuroinflammation
2012 9:202.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Xuan et al. Journal of Neuroinflammation 2012, 9:202 Page 11 of 11
http://www.jneuroinflammation.com/content/9/1/202
